Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome Therapeutics and Moderna are two companies with distinct approaches to pharmaceutical development. Axsome focuses on discovering, developing, and commercializing treatments for various central nervous system disorders. The company has several drugs in its pipeline, including Auvelity, Sunosi, and Symbravo, with the potential for future product additions.

Axsome's near-term revenue comes from these three drugs, with Auvelity projected to generate $180 million in sales annually, peaking at $8 billion, and Sunosi projected to generate $36 million annually, peaking at $300 million to $500 million.

On the other hand, Moderna is a company that researches, develops, and globally commercializes diverse therapeutic applications and preventive medicines using its proprietary messenger RNA technology. The company recently received FDA approval for its updated seasonal vaccines and priced an upsized $2.6 billion public offering of convertible senior notes.

However, Moderna's recent revenue decline can be attributed to the decreasing demand for COVID-19 vaccines and the emergence of competitors with their own vaccines. This has resulted in less-than-robust adoption of Moderna's other vaccines such as RSV, leading to a recent trend of weak revenue relative to past performance.

Comparing the two companies, Axsome Therapeutics is currently showing positive revenue trends with its three drugs driving sales, with projected peak sales of $8 billion for Auvelity and $500 million for Sunosi. In contrast, Moderna is experiencing revenue volatility as a result of its overreliance on a handful of products that have run their course. While Moderna's long-term promise remains, the recent decline in COVID-19 vaccine demand and competition in the vaccine market has negatively impacted its revenue.